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Abstract
Mycoplasma pneumoniae infections occur both endemically and epidemically, and macrolide resistance has been spreading
for 10 years worldwide. A substantial increased incidence of M. pneumoniae infections has been reported in several
countries since 2010. Whether this increased incidence is attributed to different or to the same M. pneumoniae genotype is
unknown. We have developed a multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) for the molecular typing
of M. pneumoniae isolates. In this study, the MLVA typing method was modified and validated to be applicable directly to
respiratory tract specimens without culture. This method was applied to 34 M. pneumoniae-positive specimens received at
the Bordeaux Hospital, France, between 2007 and 2010 in an endemic setting, and to 63 M. pneumoniae-positive specimens
collected during an epidemic surge of M. pneumoniae infections in 2010 in Jerusalem, Israel. The M. pneumoniae endemic
spread was shown to be polyclonal in France, with 15 MLVA types identified. Strikingly, the Israeli epidemic surge was also a
multi-clonal phenomenon, with 18 circulating MLVA types. The macrolide resistance-associated substitution, A2058G, was
found in 22% of the Israeli patients. Macrolide-resistant M. pneumoniae belonged to four MLVA types, the MLVA type Z
being the most frequent one. An association between the MLVA type Z and macrolide resistance might exist since
macrolide resistance was present or generated during the course of illness in all patients infected with this MLVA type. In
conclusion, the discriminatory power of the MLVA showed that the spread of M. pneumoniae strains in France in an endemic
setting was polyclonal as well as the surge of M. pneumoniae infections in Israel in 2010.
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Introduction
Mycoplasma pneumoniae infections occur both endemically and
epidemically worldwide, especially in children and young adults
[1]. A substantial increased incidence was reported since 2010 in
several countries of Northern Europe [2,3,4] and Israel [5,6].
Whether this increased incidence is attributed to different or to the
same M. pneumoniae genotype is unknown. To date, the typing
methods of M. pneumoniae do not allow recognition of a clonal
distribution of a strain. Indeed, until recently, the most common
typing methods of M. pneumoniae were based on the analysis of the
gene encoding the P1 protein. Several typing methods based on
this gene were developed including PCR-restriction fragment
length polymorphism (RFLP) [7,8], amplification and gene
sequencing [9], real-time PCR with high-resolution melt analysis
[10] and pyrosequencing [11]. However, isolates were poorly
differentiated due to the separation of isolates into only two types
and a few variants related to each type [12,13,14,15].
We developed a multi-locus variable-number tandem-repeat
(VNTR) analysis (MLVA) for the molecular typing of M.
pneumoniae isolates. This method is based on one-step multiplex
PCR amplifications using labelled primers and can differentiate
over 26 distinct VNTR types [16]. A correlation was found with
the P1 gene-based typing methods, but MLVA has a higher
discriminatory power. Later, a culture-independent method was
developed [17], but it remained labour-intensive and time
consuming due to the use of five independent nested PCR
reactions and electrophoresis. MLVA typing was recently applied
during an increase of M. pneumoniae infections in England and
Wales [2]. However, MLVA profiles were only obtained for 17 out
of 22 samples, which was not sufficient to assess the diversity of M.
pneumoniae types circulating during this epidemic surge.
Additionally, macrolide-resistant M. pneumoniae have been
spreading for 10 years worldwide, with prevalences ranging from
below 10% in Europe, approximately 30% in Israel [5] and up to
90% in Asia [18]. The possibility of an association between
macrolide resistance and a specific M. pneumoniae clone has never
been assessed due to the lack of a discriminatory genotyping
method.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38585To determine whether the M. pneumoniae spread is clonal or
polyclonal, we improved the MLVA typing protocol to allow for
typing of M. pneumoniae directly in respiratory tract specimens
without culture. This method was applied to 34 M. pneumoniae-
positive specimens received at the Bordeaux Hospital, France,
over the course of a 3-year endemic period and to 63 M.
pneumoniae-positive specimens collected in Jerusalem, Israel, during
2010, at which time an epidemic surge of M. pneumoniae infections
was observed. Resistance to macrolides was also assessed for a
possible association between the MLVA type and macrolide
resistance.
Materials and Methods
Ethics Statement
The present project is in compliance with the Helsinki
Declaration (Ethical Principles for Medical Research Involving
Human Subjects).
The French study was conducted in accordance with the
guidelines of the ‘‘Direction de la Recherche Clinique et de
l’Innovation’’, the research board of Bordeaux University hospital,
Bordeaux, France. All patient data were anonymously reported,
with no possibility of connecting the isolates and specimens to
individual patients. Using the written ‘‘livret d’accueil’’ of the
Bordeaux University Hospital, patients are explicitly informed at
the admission to hospital that their samples could be used for
research purposes and that they can oppose to this use. As
specimens used in this study are part of routine patient
management without any additional sampling, and since patients
provided no objection for their samples to be used, the article
L1211-2 of the French code of Public Health states that this study
did not need to be examined by the ethical committee ‘‘Comite ´d e
Protection des Personnes’’ and that patient’s informed consent was
not required.
The study at the Hadassah-Hebrew University medical center
was approved by the Hadassah-Hebrew University medical center
institutional review board without the need for informed consent,
as part of the retrospective study on the characteristics of patients
infected with M. pneumoniae. All samples were analysed anony-
mously for both resistance and typing.
Clinical Specimens and M. Pneumoniae Isolates
To compare the MLVA typing results between clinical isolates
and their original corresponding clinical specimens, 18 M.
pneumoniae isolates previously typed by the MLVA method [16]
were randomly selected. The 18 corresponding respiratory tract
specimens, stored at the Department of Bacteriology in the
University Hospital of Bordeaux, France, were thawed and
subjected to direct MLVA typing. The results were compared.
Over three years (October 1st 2007–September 30th 2010), all
the respiratory tract specimens detected positive for M. pneumo-
niae by the in-house real-time PCR [19] at the Department of
Bacteriology in the University Hospital of Bordeaux, France, were
retrospectively recorded. Available remnants of 34 specimens or
DNA extracts stored at 280uC were thawed. The M. pneumoniae
isolates that could be grown from the clinical specimens [20] were
also used for MLVA typing. DNA was extracted using the MagNA
Pure LC DNA isolation kit I (Roche Diagnostics, Frpance)
according to the manufacturer’s instructions.
Additionally, 63 throat-swab specimens positive for M. pneumo-
niae by in-house real-time PCR [5] collected from 55 patients were
used. These specimens were collected at the Hadassah-Hebrew
University Medical Centre, Jerusalem, Israel during an epidemic
surge of M. pneumoniae respiratory infections between January
1
st 2010 and December 31
st 2010. The throat-swab specimens
collected between January and August 2010 have previously been
described [5]. DNA was extracted by boiling, as previously
described [5].
Detection of Macrolide-resistance-associated Mutations
French isolates and respiratory tract specimens were analysed
using the real-time PCR and melting curve analysis method [21].
The presence of macrolide resistance-associated mutations was
confirmed by amplification and sequencing of the domain V of the
23 S rRNA gene [21]. Throat specimens from Israel were
analysed for mutations using a real-time PCR and high-resolution
melt analysis method directly from boiled extracts [5,22], and the
presence of mutations was confirmed by sequencing.
MLVA Typing
MLVA typing on M. pneumoniae isolates was performed using
two multiplex PCRs with fluorescently labelled primers targeting
five VNTR loci, followed by capillary electrophoresis [16]. The
method was adapted to be used directly on DNA extracts from
clinical specimens. Modifications concerning the sample amount
and the number of PCR cycles were required to amplify M.
pneumoniae DNA from clinical specimens. Briefly, the reaction
mixtures M1 and M2 [16] both corresponding to multiplex PCRs
were prepared in a final volume of 25 ml, with 5 ml of template
used instead of 1 ml for bacterial isolates. Both multiplex mixtures
were run using the same cycling conditions of 95uC for 15 min,
followed by 40 cycles of 95uC for 1 min, 60uC for 1 min and 72uC
for 1 min instead of 25 cycles for clinical isolates, before a final
extension of 72uC for 10 min. Electrophoresis and GeneScan
analysis were performed as previously described [16]. When an
inconsistency in the MLVA type was found between the M.
pneumoniae isolate and the clinical specimen, the relevant VNTR
locus was analysed from both the isolate and the corresponding
specimen using the nested PCR method [17].
Results
Comparison of MLVA Typing Results between
Respiratory Tract Specimens and Corresponding M.
pneumoniae Isolates
Our MLVA typing protocol was modified to allow for direct
typing on respiratory tract sample DNA extracts. To validate the
modifications, we initially tested 18 M. pneumoniae-positive respi-
ratory tract specimens from which 18 M. pneumoniae isolates had
been grown and had previously been typed by our MLVA method
[16] (Table 1). Direct typing was successful in 13 out of 18 clinical
specimens (72%). All specimens that could not be typed had low
levels of M. pneumoniae DNA. This was deduced because the cycle
thresholds exceeded 35 for the real-time PCR targeting the P1
adhesin gene that was used for primary detection of the pathogen.
The MLVA types were identical between clinical isolates and their
original clinical specimens.
MLVA Typing on French Respiratory Specimens over
Three Years in an Endemic Setting
Between October 1
st 2007 and September 30
th 2010, 35 pa-
tients were positive for M. pneumoniae using a specific real-time
PCR on their respiratory tract specimens. Thirty-four specimens,
including throat swabs, nasopharyngeal and bronchial aspirates,
sputum, broncho-alveolar lavages and pleural fluids, correspond-
ing to 30 patients, were available for MLVA typing (Table 2). M.
pneumoniae MLVA profiles were obtained for 29 specimens, leading
Polyclonality of the Mycoplasma pneumonia Spread
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38585to a sensitivity of 85% for the MLVA typing method on clinical
specimens. Fifteen distinct MLVA types were identified, 13
previously reported types (B, E, H, I, J, M, O, P, T, U, V, 27,
and profile 24672 termed MLVA-29) [16,17] as well as two new
MLVA types, termed MLVA-30 for profile 34662 and MLVA-31
for profile 84472.
Three sets of two concurrent specimens collected from the same
patient at the same time were analysed. In each case, MLVA
typing led to an identical MLVA profile for both specimens
(Table 2). It should be noted that the corresponding isolate grown
from each of these specimens also harboured the same MLVA
type (Table 2; specimens Mpn-3823/Mpn-3825, Mpn-4089/
Mpn-4097 and Mpn-4392/Mpn-4393). One patient had two M.
pneumoniae-positive specimens one year apart, in January and
December 2008 (Table 2, specimens Mpn-3920 and Mpn-4139).
MLVA typing distinguished MLVA type B and MLVA type U,
respectively. Because those MLVA profiles differ by three distinct
markers, it is plausible that this patient was re-infected by a
different M. pneumoniae strain, which also harboured an A2059G
substitution (see below).
An M. pneumoniae isolate could be grown from 19 respiratory
tract specimens (culture sensitivity =56%). The MLVA profiles
from specimens and isolates were concordant in all except two
cases. In both cases (Table 2, specimen Mpn-4736/isolate B5719
and specimen Mpn-4139/isolate B4975), we noted a change in the
number of tandem repeats of marker Mpn1, varying by two or one
repeats, respectively, and leading to a change of the MLVA type.
This discrepancy in the number of repeats at the Mpn1 locus was
confirmed using the nested PCR method applied to these clinical
specimens and M. pneumoniae isolates.
Macrolide resistance-associated mutations were searched for in
all respiratory tract specimens. Twenty-nine (85%) genotypes were
obtained. Twenty-eight (96.6%) specimens produced a melting
peak characteristic of the wild-type genotype, and only one
specimen (3.4%) harboured a macrolide-resistant A2059G geno-
type (Escherichia coli numbering, corresponding to A2064G using
M. pneumoniae numbering) (Table 2, specimen Mpn-4139). This
specimen was collected from a three-year-old boy recurrently
hospitalised for acute exacerbation of asthma and pneumonia.
From this specimen, corresponding macrolide-resistant isolate
(isolate B4975) was obtained.
MLVA Typing on Israeli Specimens Collected during a
Surge of M. pneumoniae Respiratory Tract Infections
While for the French specimens a constant rate of isolation was
observed during the 3 years of the study, a surge of M. pneumoniae-
associated respiratory tract infections was observed in 2010 at the
Hadassah-Hebrew University Medical Centre in Jerusalem. Fifty-
five patients had a positive M. pneumoniae PCR in 2010, compared
to 20 patients in 2007, two patients in 2008 and none in 2009 [6].
This finding led to the question of whether such epidemic surge
was a monoclonal phenomenon. M. pneumoniae MLVA profile was
obtained for 49 throat swab samples out of 63 (sensitivity of 78%),
corresponding to 41 patients (Table 3). Interestingly, MLVA
typing showed 18 distinct MLVA types, suggesting that the
increased incidence of M. pneumoniae was a multiclonal phenom-
enon. The MLVA type O was the most frequent type (9 patients
or 22%), followed by the MLVA type P (5 patients or 12%) and
the MLVA type Z (4 patients or 10%). No association between the
MLVA type and the month of isolation was noted. Four patients
had a couple of concurrent or subsequent specimens that led to an
identical MLVA type (Table 3, patients #4, #16, #26, #33). All
five subsequent specimens that were obtained over 23 days in
patient #2 were MLVA type Z, except one, which was categorised
as MLVA type X. This change was due to a single tandem repeat
difference for marker 1. Taking into account the possible
instability of this marker reported above, we think that the most
plausible hypothesis is that this patient was infected by a unique
MLVA type Z M. pneumoniae isolate. However, we cannot exclude
the possibility of a mixed infection by MLVA types Z and X M.
pneumoniae in this patient.
A macrolide resistance-associated mutation A2058G (E. coli
numbering, corresponding to A2063G using M. pneumoniae
numbering) was found in nine patients (22%). The comparison
between the macrolide-resistant genotype and the MLVA type
revealed that macrolide-resistant strains were found in four distinct
MLVA types, type Z, O, C and G. MLVA type Z was the most
frequent resistant type infecting four patients (44%). These
patients, patients #2, #5, #12 and #19, were aged 6, 10, 31
and 6 years, respectively. In contrast to MLVA type O, in which 6
out of 9 patients had a wild-type genotype, in MLVA type Z, all
4 patients were shown to have an A2058G substitution in the 23 S
rRNA gene. Notably, in patient #2 for whom the case report was
previously published [5], the macrolide resistance emerged during
a treatment with azithromycin.
Discussion
M. pneumoniae is a fastidious bacterium that has a low detection
sensitivity in culture. For this reason, a typing method that can be
applied directly to patient specimens is of great need. MLVA
typing methods are usually applied to bacterial isolates. In this
study, the MLVA typing method of M. pneumoniae isolates was
adapted by increase of sample amount and numbers of PCR cycles
to be applicable directly to clinical specimens without the need for
positive culture. With our method, the MLVA profile of M.
pneumoniae could be obtained directly from respiratory tract
specimens in 72–85% of cases. Specimens that failed to amplify
had low levels of M. pneumoniae DNA. As a comparison, other M.
pneumoniae PCR-based methods applied directly to clinical
specimens, such as detection of macrolide resistance-associated
mutations, also had a sensitivity below 80% [21,22] and/or a
required minimum bacterial DNA load [11].
Comparison of the results of MLVA typing between respiratory
tract specimens and M. pneumoniae isolates grown from them led to
two cases of discrepancy concerning the marker Mpn1. Moreover,
the MLVA typing of five subsequent specimens from patient #2o f
the Israeli cohort may also suggest a slight instability of marker
Mpn1. The marker Mpn1 is 12 bp long and is located in the hsdS
gene. It is the most discriminatory VNTR, with repeat copy
numbers ranging from 1 to 8. This marker was previously shown
to be stable by us [16] and others [17] in vitro after repeated
culture passages or after infection passage in guinea pigs and in
vivo using concurrent isolates. Moreover, other studies using the
same marker Mpn1 for MLVA typing from specimens did not
report any instability [2,3,17]., We suggest here that the number of
tandem repeats of marker Mpn1 may vary by one or two repeats
in a small number of cases. However, the possibility of mixed
infection by different MLVA type strains could also explain these
cases of discrepancy.
MLVA typing of M. pneumoniae is important both individually
and epidemiologically. At the level of an individual patient, it
allows the discrimination of relapse or persistence from repeated
infections. In the first case, the MLVA type remains identical. In
case of a re-infection, the MLVA type is likely to be different. At
the population level, MLVA typing assesses the diversity of M.
pneumoniae strains that are circulating in a community or during an
epidemic surge. In this study, we showed that the M. pneumoniae
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38585Table 3. Characteristics of 49 M. pneumoniae-positive throat swab specimens collected at the Hadassah-Hebrew University
Medical Center, Jerusalem, Israel in 2010, from 41 patients.
Specimen
designation
Patient
number
Date of collection Mpn 1 Mpn 13 Mpn 14 Mpn 15 Mpn 16 MLVA type Macrolide-resistance
genotype
a
P3001246 1 February 3 3 46623 0 w t
P3001235
b 2F e b r u a r y 174572Z w t
P3001259
b 2F e b r u a r y 864572X w t
P3001279
b 2F e b r u a r y 1 1 74572Z A 2 0 5 8 A / G
c
P3001306
b 2F e b r u a r y 2 2 74572Z A 2 0 5 8 G
P3001309
b 2F e b r u a r y 2 3 74572Z A 2 0 5 8 G
P3001305 3 February 22 4 4572P w t
P3001433
d 4 March 18 2 3662C w t
P3001434
d 4 March 18 2 3662C w t
P3001451 5 March 23 7 4572Z A 2 0 5 8 G
P3001482 6 April 6 3 3662H w t
P3001487 7 April 6 5 3662T w t
P3001502 8 April 11 4 4572P w t
P3001531 9 April 15 4 3662O w t
P3001538 10 April 18 4 4572P w t
P3001561 11 April 25 5 3662T w t
P3001600 12 May 3 7 4572Z A 2 0 5 8 G
P3001625 13 May 13 2 4572E w t
P3001626 14 May 13 2 4572E w t
P3001634 15 May 17 4 4572P w t
P3001726
b 1 6 J u n e 8 43662O w t
P3001741
b 1 6 J u n e 1 3 43662O w t
P3001794 17 June 29 4 3662O w t
P3001810 18 July 4 4 3662O A 2 0 5 8 A / G
c
P3001823 19 July 7 7 4572Z A 2 0 5 8 G
P3001844 20 July 14 6 4572X w t
P3001845 21 July 15 4 3662O A 2 0 5 8 G
P3001858 22 July 20 2 3662C A 2 0 5 8 G
P3001909 23 August 5 3 3562G A 2 0 5 8 G
P3001923 24 August 9 1 4572A w t
P3001928 25 August 9 4 3662O w t
P3001936
b 26 August 11 5 3562S w t
P3001940
b 26 August 12 5 3562S w t
P3001939 27 August 12 6 3562V w t
P3002039 28 October 3 5 4572U w t
P3002040 29 October 3 5 3562S w t
P3002068 30 October 11 6 3662W w t
P3002077 31 October 13 5 4572U w t
P3002079 32 October 13 2 3662C w t
P3002081
b 3 3 O c t o b e r 1 743662O w t
P3002263
b 3 3 N o v e m b e r 2 9 43662O w t
P3002160 34 October 31 4 4572P w t
P3002161 35 October 31 3 4572J w t
P3002167 36 November 1 5 4572U w t
P3002175 37 November 3 5 3562S w t
P3002185 38 November 8 2 3562B w t
P3002202 39 November 11 3 4562K n o a m p
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without any predominating MLVA type. This observation could
be attributed to the absence of an epidemic surge of M. pneumoniae
observed there during this period. This diversity of M. pneumoniae
MLVA types was previously reported in France [16]. The
respiratory tract specimens from Israel were collected during an
epidemic surge of M. pneumoniae infections. However, in contrast to
the clonal spread that could have been expected, the MLVA
typing revealed that this epidemic surge was a multi-clonal
phenomenon, with 18 distinct circulating MLVA types. Three
MLVA types, O, P and Z, were predominant and were found in
44% of patients. MLVA types O and P were previously shown to
be frequent MLVA types [16]. On the contrary, MLVA type Z is
not a frequent MLVA type because it was found before in only
1.9% of M. pneumoniae isolates [16]. Interestingly, macrolide
resistance was found or was generated during the course of
infection in all the patients infected with an MLVA type Z strain.
The patients were not related since they came from different
families, neighbourhoods and religious communities. Although the
number of those patients remained limited, there might be an
association between the MLVA type Z and macrolide resistance in
Jerusalem. However, it is not possible to conclude whether MLVA
type Z strains are more prone to acquire macrolide resistance-
associated mutations or whether a macrolide-resistant M.
pneumoniae clone is spreading in Jerusalem. One study reported a
strong association between the P1 gene PCR-RFLP type 1 and
erythromycin resistance in Shanghai [23]. However, because the
macrolide-resistance rate is high in Asia [18] and because the
PCR-RFLP typing method only separates two different types,
these resistant strains may not necessarily belong to the same
clone. In Beijing, type 1 macrolide-resistant M. pneumoniae isolates
were recently shown to belong to different clones based on the
study of a single VNTR that exists in P1 cytadhesin gene
(MPN141) [24]. Finally, the determination of both the macrolide-
resistant genotype and the MLVA type needs to be continued on
M. pneumoniae-positive respiratory tract specimens collected in
Jerusalem to assess the possibility of an association between the
MLVA type Z and macrolide resistance.
In summary, the discriminatory power of the MLVA method
showed that the spread of M. pneumoniae strains in France over
three years in an endemic setting was polyclonal. Moreover, the
surge of M. pneumoniae infections in Israel in 2010 was not
attributed to the spread of a single clone but was also a polyclonal
phenomenon.
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